Good
Partially Aligned
Patient Risk:
Low
Summary
One claim is directly supported by the provided FDA label excerpts (premature discontinuation increases thrombotic events). However, several other claims about FDA approval timing and U.S./EU launch dates are not supported by the supplied labeling content, resulting in partial misalignment.
Category Scores
Accurate Statements
Premature discontinuation of XARELTO increases the risk of thrombotic events.
Supported by BOX (Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events) and Section 5.1 (premature discontinuation... increases the risk of thrombotic events).
Unsupported Statements
Xarelto (rivaroxaban) was first approved by the U.S. Food and Drug Administration (FDA).
The provided FDA prescribing information excerpts do not include approval history or first approval statements; the claim cannot be verified from the supplied label text.
Xarelto (rivaroxaban) was launched in the U.S. in 2011.
The provided label excerpts do not include U.S. launch date information.
The provided source does not specify the exact month in 2011 when Xarelto was approved.
The assessment relies on information not present in the supplied prescribing information excerpts; the excerpts do not address approval month.
The provided source does not provide an EU start date for Xarelto availability.
The provided label excerpts do not include EU availability/start date information.
Contradictions
Important Omissions
No label-informative details are provided for approval/launch date claims; if such claims are to be evaluated, the FDA label text excerpt must include relevant approval/marketing history (not present in the supplied excerpts).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only directly label-evaluable safety claim provided (premature discontinuation increases thrombotic events) is supported by boxed warning/Section 5.1.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Claims about FDA approval and U.S./EU launch dates are not supported by the provided prescribing information excerpts.
Suggested Improvement
Restrict evaluations to statements explicitly supported by the provided FDA label text (e.g., boxed warning and Section 5.1 for discontinuation risk) and omit or re-source approval/launch-date claims from label sections that contain such information.